Global Gene Therapy for Neurodegenerative Diseases Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Gene Therapy for Neurodegenerative Diseases market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Gene Therapy for Neurodegenerative Diseases industry chain, the market status of Hospitals and Clinics (Gene Replacement Therapy, Gene Silencing Therapy), Research Institutions (Gene Replacement Therapy, Gene Silencing Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Gene Therapy for Neurodegenerative Diseases.
Regionally, the report analyzes the Gene Therapy for Neurodegenerative Diseases markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Gene Therapy for Neurodegenerative Diseases market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Gene Therapy for Neurodegenerative Diseases market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Gene Therapy for Neurodegenerative Diseases industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Gene Replacement Therapy, Gene Silencing Therapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Gene Therapy for Neurodegenerative Diseases market.
Regional Analysis: The report involves examining the Gene Therapy for Neurodegenerative Diseases market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Gene Therapy for Neurodegenerative Diseases market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Gene Therapy for Neurodegenerative Diseases:
Company Analysis: Report covers individual Gene Therapy for Neurodegenerative Diseases players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Gene Therapy for Neurodegenerative Diseases This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals and Clinics, Research Institutions).
Technology Analysis: Report covers specific technologies relevant to Gene Therapy for Neurodegenerative Diseases. It assesses the current state, advancements, and potential future developments in Gene Therapy for Neurodegenerative Diseases areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Gene Therapy for Neurodegenerative Diseases market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Gene Therapy for Neurodegenerative Diseases market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Gene Therapy for Neurodegenerative Diseases product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapy for Neurodegenerative Diseases, with revenue, gross margin and global market share of Gene Therapy for Neurodegenerative Diseases from 2018 to 2023.
Chapter 3, the Gene Therapy for Neurodegenerative Diseases competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy for Neurodegenerative Diseases market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy for Neurodegenerative Diseases.
Chapter 13, to describe Gene Therapy for Neurodegenerative Diseases research findings and conclusion.
The Global Info Research report includes an overview of the development of the Gene Therapy for Neurodegenerative Diseases industry chain, the market status of Hospitals and Clinics (Gene Replacement Therapy, Gene Silencing Therapy), Research Institutions (Gene Replacement Therapy, Gene Silencing Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Gene Therapy for Neurodegenerative Diseases.
Regionally, the report analyzes the Gene Therapy for Neurodegenerative Diseases markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Gene Therapy for Neurodegenerative Diseases market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Gene Therapy for Neurodegenerative Diseases market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Gene Therapy for Neurodegenerative Diseases industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Gene Replacement Therapy, Gene Silencing Therapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Gene Therapy for Neurodegenerative Diseases market.
Regional Analysis: The report involves examining the Gene Therapy for Neurodegenerative Diseases market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Gene Therapy for Neurodegenerative Diseases market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Gene Therapy for Neurodegenerative Diseases:
Company Analysis: Report covers individual Gene Therapy for Neurodegenerative Diseases players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Gene Therapy for Neurodegenerative Diseases This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals and Clinics, Research Institutions).
Technology Analysis: Report covers specific technologies relevant to Gene Therapy for Neurodegenerative Diseases. It assesses the current state, advancements, and potential future developments in Gene Therapy for Neurodegenerative Diseases areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Gene Therapy for Neurodegenerative Diseases market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Gene Therapy for Neurodegenerative Diseases market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Gene Replacement Therapy
- Gene Silencing Therapy
- Gene Editing Therapy
- Enzyme Replacement Therapy
- Hospitals and Clinics
- Research Institutions
- Biotechnology Companies
- Others
- Voyager Therapeutics
- Uniqure N.V.
- Axovant Gene Therapies
- Novartis Ag
- Amicus Therapeutics
- Regenxbio Inc.
- Sarepta Therapeutics
- Gensight Biologics
- Krystal Biotech
- Avexis
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Gene Therapy for Neurodegenerative Diseases product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapy for Neurodegenerative Diseases, with revenue, gross margin and global market share of Gene Therapy for Neurodegenerative Diseases from 2018 to 2023.
Chapter 3, the Gene Therapy for Neurodegenerative Diseases competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy for Neurodegenerative Diseases market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy for Neurodegenerative Diseases.
Chapter 13, to describe Gene Therapy for Neurodegenerative Diseases research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Gene Therapy for Neurodegenerative Diseases
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Therapy for Neurodegenerative Diseases by Type
1.3.1 Overview: Global Gene Therapy for Neurodegenerative Diseases Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type in 2022
1.3.3 Gene Replacement Therapy
1.3.4 Gene Silencing Therapy
1.3.5 Gene Editing Therapy
1.3.6 Enzyme Replacement Therapy
1.4 Global Gene Therapy for Neurodegenerative Diseases Market by Application
1.4.1 Overview: Global Gene Therapy for Neurodegenerative Diseases Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals and Clinics
1.4.3 Research Institutions
1.4.4 Biotechnology Companies
1.4.5 Others
1.5 Global Gene Therapy for Neurodegenerative Diseases Market Size & Forecast
1.6 Global Gene Therapy for Neurodegenerative Diseases Market Size and Forecast by Region
1.6.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region, (2018-2029)
1.6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.6 South America Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Voyager Therapeutics
2.1.1 Voyager Therapeutics Details
2.1.2 Voyager Therapeutics Major Business
2.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Voyager Therapeutics Recent Developments and Future Plans
2.2 Uniqure N.V.
2.2.1 Uniqure N.V. Details
2.2.2 Uniqure N.V. Major Business
2.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Uniqure N.V. Recent Developments and Future Plans
2.3 Axovant Gene Therapies
2.3.1 Axovant Gene Therapies Details
2.3.2 Axovant Gene Therapies Major Business
2.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Axovant Gene Therapies Recent Developments and Future Plans
2.4 Novartis Ag
2.4.1 Novartis Ag Details
2.4.2 Novartis Ag Major Business
2.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Ag Recent Developments and Future Plans
2.5 Amicus Therapeutics
2.5.1 Amicus Therapeutics Details
2.5.2 Amicus Therapeutics Major Business
2.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amicus Therapeutics Recent Developments and Future Plans
2.6 Regenxbio Inc.
2.6.1 Regenxbio Inc. Details
2.6.2 Regenxbio Inc. Major Business
2.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Regenxbio Inc. Recent Developments and Future Plans
2.7 Sarepta Therapeutics
2.7.1 Sarepta Therapeutics Details
2.7.2 Sarepta Therapeutics Major Business
2.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Sarepta Therapeutics Recent Developments and Future Plans
2.8 Gensight Biologics
2.8.1 Gensight Biologics Details
2.8.2 Gensight Biologics Major Business
2.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gensight Biologics Recent Developments and Future Plans
2.9 Krystal Biotech
2.9.1 Krystal Biotech Details
2.9.2 Krystal Biotech Major Business
2.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Krystal Biotech Recent Developments and Future Plans
2.10 Avexis
2.10.1 Avexis Details
2.10.2 Avexis Major Business
2.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Avexis Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Gene Therapy for Neurodegenerative Diseases Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gene Therapy for Neurodegenerative Diseases by Company Revenue
3.2.2 Top 3 Gene Therapy for Neurodegenerative Diseases Players Market Share in 2022
3.2.3 Top 6 Gene Therapy for Neurodegenerative Diseases Players Market Share in 2022
3.3 Gene Therapy for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.3.1 Gene Therapy for Neurodegenerative Diseases Market: Region Footprint
3.3.2 Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
3.3.3 Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Gene Therapy for Neurodegenerative Diseases Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2023)
5.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
6.2 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country
6.3.1 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
6.3.2 United States Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
6.3.3 Canada Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
6.3.4 Mexico Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country
7.3.1 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
7.3.2 Germany Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.3 France Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.5 Russia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.6 Italy Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region
8.3.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2029)
8.3.2 China Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.3 Japan Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.4 South Korea Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.5 India Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.7 Australia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
9.2 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
9.3 South America Gene Therapy for Neurodegenerative Diseases Market Size by Country
9.3.1 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
9.3.2 Brazil Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
9.3.3 Argentina Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country
10.3.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
10.3.2 Turkey Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10.3.4 UAE Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Gene Therapy for Neurodegenerative Diseases Market Drivers
11.2 Gene Therapy for Neurodegenerative Diseases Market Restraints
11.3 Gene Therapy for Neurodegenerative Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Gene Therapy for Neurodegenerative Diseases Industry Chain
12.2 Gene Therapy for Neurodegenerative Diseases Upstream Analysis
12.3 Gene Therapy for Neurodegenerative Diseases Midstream Analysis
12.4 Gene Therapy for Neurodegenerative Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Gene Therapy for Neurodegenerative Diseases
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Therapy for Neurodegenerative Diseases by Type
1.3.1 Overview: Global Gene Therapy for Neurodegenerative Diseases Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type in 2022
1.3.3 Gene Replacement Therapy
1.3.4 Gene Silencing Therapy
1.3.5 Gene Editing Therapy
1.3.6 Enzyme Replacement Therapy
1.4 Global Gene Therapy for Neurodegenerative Diseases Market by Application
1.4.1 Overview: Global Gene Therapy for Neurodegenerative Diseases Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals and Clinics
1.4.3 Research Institutions
1.4.4 Biotechnology Companies
1.4.5 Others
1.5 Global Gene Therapy for Neurodegenerative Diseases Market Size & Forecast
1.6 Global Gene Therapy for Neurodegenerative Diseases Market Size and Forecast by Region
1.6.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region, (2018-2029)
1.6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.6 South America Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gene Therapy for Neurodegenerative Diseases Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Voyager Therapeutics
2.1.1 Voyager Therapeutics Details
2.1.2 Voyager Therapeutics Major Business
2.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Voyager Therapeutics Recent Developments and Future Plans
2.2 Uniqure N.V.
2.2.1 Uniqure N.V. Details
2.2.2 Uniqure N.V. Major Business
2.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Uniqure N.V. Recent Developments and Future Plans
2.3 Axovant Gene Therapies
2.3.1 Axovant Gene Therapies Details
2.3.2 Axovant Gene Therapies Major Business
2.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Axovant Gene Therapies Recent Developments and Future Plans
2.4 Novartis Ag
2.4.1 Novartis Ag Details
2.4.2 Novartis Ag Major Business
2.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Ag Recent Developments and Future Plans
2.5 Amicus Therapeutics
2.5.1 Amicus Therapeutics Details
2.5.2 Amicus Therapeutics Major Business
2.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amicus Therapeutics Recent Developments and Future Plans
2.6 Regenxbio Inc.
2.6.1 Regenxbio Inc. Details
2.6.2 Regenxbio Inc. Major Business
2.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Regenxbio Inc. Recent Developments and Future Plans
2.7 Sarepta Therapeutics
2.7.1 Sarepta Therapeutics Details
2.7.2 Sarepta Therapeutics Major Business
2.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Sarepta Therapeutics Recent Developments and Future Plans
2.8 Gensight Biologics
2.8.1 Gensight Biologics Details
2.8.2 Gensight Biologics Major Business
2.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gensight Biologics Recent Developments and Future Plans
2.9 Krystal Biotech
2.9.1 Krystal Biotech Details
2.9.2 Krystal Biotech Major Business
2.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Krystal Biotech Recent Developments and Future Plans
2.10 Avexis
2.10.1 Avexis Details
2.10.2 Avexis Major Business
2.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product and Solutions
2.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Avexis Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Gene Therapy for Neurodegenerative Diseases Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gene Therapy for Neurodegenerative Diseases by Company Revenue
3.2.2 Top 3 Gene Therapy for Neurodegenerative Diseases Players Market Share in 2022
3.2.3 Top 6 Gene Therapy for Neurodegenerative Diseases Players Market Share in 2022
3.3 Gene Therapy for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.3.1 Gene Therapy for Neurodegenerative Diseases Market: Region Footprint
3.3.2 Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
3.3.3 Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Gene Therapy for Neurodegenerative Diseases Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2023)
5.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
6.2 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country
6.3.1 North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
6.3.2 United States Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
6.3.3 Canada Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
6.3.4 Mexico Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country
7.3.1 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
7.3.2 Germany Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.3 France Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.5 Russia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
7.3.6 Italy Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region
8.3.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2029)
8.3.2 China Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.3 Japan Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.4 South Korea Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.5 India Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
8.3.7 Australia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
9.2 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
9.3 South America Gene Therapy for Neurodegenerative Diseases Market Size by Country
9.3.1 South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
9.3.2 Brazil Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
9.3.3 Argentina Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country
10.3.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2029)
10.3.2 Turkey Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
10.3.4 UAE Gene Therapy for Neurodegenerative Diseases Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Gene Therapy for Neurodegenerative Diseases Market Drivers
11.2 Gene Therapy for Neurodegenerative Diseases Market Restraints
11.3 Gene Therapy for Neurodegenerative Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Gene Therapy for Neurodegenerative Diseases Industry Chain
12.2 Gene Therapy for Neurodegenerative Diseases Upstream Analysis
12.3 Gene Therapy for Neurodegenerative Diseases Midstream Analysis
12.4 Gene Therapy for Neurodegenerative Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Voyager Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Voyager Therapeutics Major Business
Table 7. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 8. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Voyager Therapeutics Recent Developments and Future Plans
Table 10. Uniqure N.V. Company Information, Head Office, and Major Competitors
Table 11. Uniqure N.V. Major Business
Table 12. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 13. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Uniqure N.V. Recent Developments and Future Plans
Table 15. Axovant Gene Therapies Company Information, Head Office, and Major Competitors
Table 16. Axovant Gene Therapies Major Business
Table 17. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 18. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Axovant Gene Therapies Recent Developments and Future Plans
Table 20. Novartis Ag Company Information, Head Office, and Major Competitors
Table 21. Novartis Ag Major Business
Table 22. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 23. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Novartis Ag Recent Developments and Future Plans
Table 25. Amicus Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Amicus Therapeutics Major Business
Table 27. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 28. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Amicus Therapeutics Recent Developments and Future Plans
Table 30. Regenxbio Inc. Company Information, Head Office, and Major Competitors
Table 31. Regenxbio Inc. Major Business
Table 32. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 33. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Regenxbio Inc. Recent Developments and Future Plans
Table 35. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 38. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Sarepta Therapeutics Recent Developments and Future Plans
Table 40. Gensight Biologics Company Information, Head Office, and Major Competitors
Table 41. Gensight Biologics Major Business
Table 42. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 43. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gensight Biologics Recent Developments and Future Plans
Table 45. Krystal Biotech Company Information, Head Office, and Major Competitors
Table 46. Krystal Biotech Major Business
Table 47. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 48. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Krystal Biotech Recent Developments and Future Plans
Table 50. Avexis Company Information, Head Office, and Major Competitors
Table 51. Avexis Major Business
Table 52. Avexis Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 53. Avexis Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Avexis Recent Developments and Future Plans
Table 55. Global Gene Therapy for Neurodegenerative Diseases Revenue (USD Million) by Players (2018-2023)
Table 56. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Players (2018-2023)
Table 57. Breakdown of Gene Therapy for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Gene Therapy for Neurodegenerative Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Gene Therapy for Neurodegenerative Diseases Players
Table 60. Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 61. Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 62. Gene Therapy for Neurodegenerative Diseases New Market Entrants and Barriers to Market Entry
Table 63. Gene Therapy for Neurodegenerative Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Gene Therapy for Neurodegenerative Diseases Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Type (2018-2023)
Table 66. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Type (2024-2029)
Table 67. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023)
Table 68. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Application (2024-2029)
Table 69. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Gene Therapy for Neurodegenerative Diseases Raw Material
Table 100. Key Suppliers of Gene Therapy for Neurodegenerative Diseases Raw Materials
Table 1. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Voyager Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Voyager Therapeutics Major Business
Table 7. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 8. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Voyager Therapeutics Recent Developments and Future Plans
Table 10. Uniqure N.V. Company Information, Head Office, and Major Competitors
Table 11. Uniqure N.V. Major Business
Table 12. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 13. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Uniqure N.V. Recent Developments and Future Plans
Table 15. Axovant Gene Therapies Company Information, Head Office, and Major Competitors
Table 16. Axovant Gene Therapies Major Business
Table 17. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 18. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Axovant Gene Therapies Recent Developments and Future Plans
Table 20. Novartis Ag Company Information, Head Office, and Major Competitors
Table 21. Novartis Ag Major Business
Table 22. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 23. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Novartis Ag Recent Developments and Future Plans
Table 25. Amicus Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Amicus Therapeutics Major Business
Table 27. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 28. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Amicus Therapeutics Recent Developments and Future Plans
Table 30. Regenxbio Inc. Company Information, Head Office, and Major Competitors
Table 31. Regenxbio Inc. Major Business
Table 32. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 33. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Regenxbio Inc. Recent Developments and Future Plans
Table 35. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 38. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Sarepta Therapeutics Recent Developments and Future Plans
Table 40. Gensight Biologics Company Information, Head Office, and Major Competitors
Table 41. Gensight Biologics Major Business
Table 42. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 43. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gensight Biologics Recent Developments and Future Plans
Table 45. Krystal Biotech Company Information, Head Office, and Major Competitors
Table 46. Krystal Biotech Major Business
Table 47. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 48. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Krystal Biotech Recent Developments and Future Plans
Table 50. Avexis Company Information, Head Office, and Major Competitors
Table 51. Avexis Major Business
Table 52. Avexis Gene Therapy for Neurodegenerative Diseases Product and Solutions
Table 53. Avexis Gene Therapy for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Avexis Recent Developments and Future Plans
Table 55. Global Gene Therapy for Neurodegenerative Diseases Revenue (USD Million) by Players (2018-2023)
Table 56. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Players (2018-2023)
Table 57. Breakdown of Gene Therapy for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Gene Therapy for Neurodegenerative Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Gene Therapy for Neurodegenerative Diseases Players
Table 60. Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 61. Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 62. Gene Therapy for Neurodegenerative Diseases New Market Entrants and Barriers to Market Entry
Table 63. Gene Therapy for Neurodegenerative Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Gene Therapy for Neurodegenerative Diseases Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Type (2018-2023)
Table 66. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Type (2024-2029)
Table 67. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023)
Table 68. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Application (2024-2029)
Table 69. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Gene Therapy for Neurodegenerative Diseases Raw Material
Table 100. Key Suppliers of Gene Therapy for Neurodegenerative Diseases Raw Materials
LIST OF FIGURES
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type in 2022
Figure 4. Gene Replacement Therapy
Figure 5. Gene Silencing Therapy
Figure 6. Gene Editing Therapy
Figure 7. Enzyme Replacement Therapy
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application in 2022
Figure 10. Hospitals and Clinics Picture
Figure 11. Research Institutions Picture
Figure 12. Biotechnology Companies Picture
Figure 13. Others Picture
Figure 14. Global Gene Therapy for Neurodegenerative Diseases Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Gene Therapy for Neurodegenerative Diseases Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region in 2022
Figure 19. North America Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Players in 2022
Figure 25. Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Gene Therapy for Neurodegenerative Diseases Market Share in 2022
Figure 27. Global Top 6 Players Gene Therapy for Neurodegenerative Diseases Market Share in 2022
Figure 28. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Type (2018-2023)
Figure 29. Global Gene Therapy for Neurodegenerative Diseases Market Share Forecast by Type (2024-2029)
Figure 30. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Application (2018-2023)
Figure 31. Global Gene Therapy for Neurodegenerative Diseases Market Share Forecast by Application (2024-2029)
Figure 32. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 42. France Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 49. China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 52. India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 66. Gene Therapy for Neurodegenerative Diseases Market Drivers
Figure 67. Gene Therapy for Neurodegenerative Diseases Market Restraints
Figure 68. Gene Therapy for Neurodegenerative Diseases Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Gene Therapy for Neurodegenerative Diseases in 2022
Figure 71. Manufacturing Process Analysis of Gene Therapy for Neurodegenerative Diseases
Figure 72. Gene Therapy for Neurodegenerative Diseases Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type in 2022
Figure 4. Gene Replacement Therapy
Figure 5. Gene Silencing Therapy
Figure 6. Gene Editing Therapy
Figure 7. Enzyme Replacement Therapy
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application in 2022
Figure 10. Hospitals and Clinics Picture
Figure 11. Research Institutions Picture
Figure 12. Biotechnology Companies Picture
Figure 13. Others Picture
Figure 14. Global Gene Therapy for Neurodegenerative Diseases Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Gene Therapy for Neurodegenerative Diseases Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region in 2022
Figure 19. North America Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Players in 2022
Figure 25. Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Gene Therapy for Neurodegenerative Diseases Market Share in 2022
Figure 27. Global Top 6 Players Gene Therapy for Neurodegenerative Diseases Market Share in 2022
Figure 28. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Type (2018-2023)
Figure 29. Global Gene Therapy for Neurodegenerative Diseases Market Share Forecast by Type (2024-2029)
Figure 30. Global Gene Therapy for Neurodegenerative Diseases Consumption Value Share by Application (2018-2023)
Figure 31. Global Gene Therapy for Neurodegenerative Diseases Market Share Forecast by Application (2024-2029)
Figure 32. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 42. France Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 49. China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 52. India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 66. Gene Therapy for Neurodegenerative Diseases Market Drivers
Figure 67. Gene Therapy for Neurodegenerative Diseases Market Restraints
Figure 68. Gene Therapy for Neurodegenerative Diseases Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Gene Therapy for Neurodegenerative Diseases in 2022
Figure 71. Manufacturing Process Analysis of Gene Therapy for Neurodegenerative Diseases
Figure 72. Gene Therapy for Neurodegenerative Diseases Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
